Viridian reported $24.7M in Lumvoa net product revenue with 100+ patients on therapy in Q3 2026. The company currently holds $955.2M in cash and announced the initiation of a phase 1 trial for VRDN-292 in Q4 2026.
Viridian reported $24.7M in Lumvoa net product revenue with 100+ patients on therapy in Q3 2026. The company currently holds $955.2M in cash and announced the initiation of a phase 1 trial for VRDN-292 in Q4 2026.